Savara (SVRA): Molbreevi De-Risking and Enhanced aPAP Market Visibility Support Higher Target and Buy Rating
I'm PortAI, I can summarize articles.
Andrew Fein from H.C. Wainwright maintains a Buy rating on Savara (SVRA) with a $10.00 price target, citing improved risk-reward profile due to successful Molbreevi BLA resubmission with Fujifilm Diosynth, Priority Review request, and operational readiness for aPAP market. Fein highlights Savara's strengthened balance sheet and non-dilutive debt financing as factors supporting the company's launch activities without excessive equity dilution. LifeSci Capital also maintains a Buy rating with an $11.00 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments